MX2019006631A - Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. - Google Patents

Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.

Info

Publication number
MX2019006631A
MX2019006631A MX2019006631A MX2019006631A MX2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A
Authority
MX
Mexico
Prior art keywords
cells
drug
nucleic acid
transcription factor
inducible
Prior art date
Application number
MX2019006631A
Other languages
English (en)
Spanish (es)
Inventor
C Jensen Michael
Ooi Tracy
Wei Jia
Original Assignee
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital Dba Seattle Childrens Res Inst filed Critical Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Publication of MX2019006631A publication Critical patent/MX2019006631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
MX2019006631A 2016-12-12 2017-12-11 Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. MX2019006631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662433183P 2016-12-12 2016-12-12
PCT/US2017/065597 WO2018111763A1 (en) 2016-12-12 2017-12-11 Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Publications (1)

Publication Number Publication Date
MX2019006631A true MX2019006631A (es) 2019-11-12

Family

ID=62559136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006631A MX2019006631A (es) 2016-12-12 2017-12-11 Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.

Country Status (8)

Country Link
US (2) US11408005B2 (enExample)
EP (1) EP3551197B1 (enExample)
JP (2) JP7091357B2 (enExample)
CN (1) CN110291200B (enExample)
AU (1) AU2017375630B2 (enExample)
CA (1) CA3045665A1 (enExample)
MX (1) MX2019006631A (enExample)
WO (1) WO2018111763A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
RU2016143389A (ru) 2014-04-10 2018-05-15 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
MX2019006631A (es) * 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
BR112020015884A2 (pt) * 2018-02-06 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
WO2020014366A1 (en) * 2018-07-10 2020-01-16 Intrexon Corporation Ror-1 specific chimeric antigen receptors and uses thereof
EP3845564A4 (en) * 2018-08-28 2022-05-18 Immunotech Biopharm Co., Ltd. ENHANCED THERAPEUTIC T LYMPHOCYTE
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
CN113423720A (zh) * 2019-02-04 2021-09-21 国立大学法人爱媛大学 CAR文库和scFv的制造方法
JP7602475B2 (ja) * 2019-03-08 2024-12-18 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
WO2020185917A1 (en) * 2019-03-13 2020-09-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers
WO2020219425A1 (en) * 2019-04-25 2020-10-29 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
WO2020257823A2 (en) * 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
AU2020399805A1 (en) * 2019-12-12 2022-07-07 Senti Biosciences, Inc. Method and compositions for regulated armoring of cells
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CA3186029A1 (en) * 2020-06-08 2021-12-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-cd171 chimeric antigen receptors
CN111848819A (zh) * 2020-07-31 2020-10-30 广东昭泰体内生物医药科技有限公司 一种靶向msln的嵌合抗原受体及其应用
US20230374104A1 (en) * 2020-10-09 2023-11-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising pd1 chimeric polypeptides
WO2022125387A1 (en) * 2020-12-08 2022-06-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
AU2022220770A1 (en) * 2021-02-12 2023-09-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Activity-inducible fusion proteins having a heat shock protein 90 binding domain
WO2022221592A2 (en) * 2021-04-15 2022-10-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for producing and using cell-based immunotherapies to target tumors
EP4341283A4 (en) * 2021-05-14 2025-06-25 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Activity-inducible fusion proteins with a transcription factor and a heat shock protein 90 binding domain
CN116813773B (zh) * 2021-12-29 2024-07-19 华道(上海)生物医药有限公司 一种抗IL13Ra2的纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
JPH07507278A (ja) 1992-06-01 1995-08-10 ニューイングランド　メディカル　センター　ホスピタルズ　インク Ｃｄ４３キメラ分子による細胞間相互作用の阻害
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
GB0015119D0 (en) 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
WO2002097050A2 (en) * 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
MXPA04009809A (es) 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004092338A2 (en) 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
EP1649020B1 (en) 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
US20070087346A1 (en) 2003-10-24 2007-04-19 Gennaro Ciliberto Orthogonal gene switches
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
US8148129B2 (en) * 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103442768A (zh) 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 治疗癌的组合物和方法
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
WO2012140130A1 (en) 2011-04-13 2012-10-18 Immunicum Ab Method for proliferation of antigen-specific t cells
BR112013029746B1 (pt) 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag método para a produção recombinante de um complexo, complexo, formulação farmacêutica e uso do complexo
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
ES2816450T3 (es) 2012-02-22 2021-04-05 Univ Pennsylvania Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
RU2650805C2 (ru) 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
US9540657B2 (en) 2012-05-25 2017-01-10 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US20150376645A1 (en) 2012-05-30 2015-12-31 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
CN104350709B (zh) 2012-06-01 2018-03-13 日本电气株式会社 交换机系统、线路卡、交换卡、fdb学习方法及fdb学习调停方法
MX380109B (es) 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star Metodo y composiciones para inmunoterapia celular.
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
ES2671004T3 (es) 2013-03-07 2018-06-04 Baylor College Of Medicine Dirección a CD138 en cáncer
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
RU2717984C2 (ru) 2013-11-21 2020-03-27 ЮСиЭл БИЗНЕС ЛТД Клетка
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
RU2016143389A (ru) 2014-04-10 2018-05-15 Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
EP3411393B1 (en) 2016-02-05 2021-04-07 City of Hope Administration of engineered t cells for treatment of cancers in the central nervous system
MX2019006631A (es) 2016-12-12 2019-11-12 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.

Also Published As

Publication number Publication date
EP3551197A4 (en) 2020-10-28
WO2018111763A9 (en) 2018-07-19
EP3551197B1 (en) 2023-11-22
US20220411805A1 (en) 2022-12-29
JP7091357B2 (ja) 2022-06-27
US11408005B2 (en) 2022-08-09
JP2022130485A (ja) 2022-09-06
WO2018111763A1 (en) 2018-06-21
CN110291200B (zh) 2024-05-14
JP7392043B2 (ja) 2023-12-05
CN110291200A (zh) 2019-09-27
US20200181624A1 (en) 2020-06-11
JP2020500563A (ja) 2020-01-16
EP3551197A1 (en) 2019-10-16
AU2017375630A1 (en) 2019-06-13
CA3045665A1 (en) 2018-06-21
AU2017375630B2 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
MX2019006631A (es) Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
CY1120980T1 (el) Μεθοδοι παρασκευης για τον ελεγχο της περιεκτικοτητας σε c-τελικη λυσινη, γαλακτοζη και σιαλικο οξυ σε ανασυνδυασμενες πρωτεϊνες
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
MX2020001791A (es) Modificacion de celulas t.
EA201891092A1 (ru) Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
RU2019127316A (ru) Рнк-направляемая инженерия генома человека
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
HRP20191907T1 (hr) 3´utr sekvence za stabilizaciju rnk
RU2017134741A (ru) Полипептиды транспозазы и их применение
AR080942A1 (es) Produccion de proteinas heteromultimericas
EA201891681A1 (ru) Новая иммуностимулирующая векторная система
CL2009000123A1 (es) Anticuerpo humanizado o fragmento de union del mismo especifico para el factor von willebrand (vwf); acido nucleico codificante; vector y celulas huesped; metodo para producir dicho anticuerpo humanizado; composicion que lo comprende; uso medico del mismo para tratar un trastorno mediado por vwf; usos no terapeuticos
AR084208A1 (es) Moduladores del ligando de efrina a (efna) y metodos para su uso
CL2014001317A1 (es) Polipeptido aislado que tiene actividad de lisozima; polinucleotido aislado que lo codifica; construccion de acido nucleico o vector de expresion; celula huesped recombinante; metodo de produccion; composicion que lo comprende, ya sea detergente o de alimentacion animal o aditivo de alimentacion animal; y su uso.
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
AR097493A1 (es) Constructos para expresar transgenes con el uso de elementos reguladores provenientes de genes ubiquitina de brachypodium
JP2015525065A5 (enExample)
RU2019124678A (ru) Слитый белок pd1-41bbl и способы его применения
BR112016015424A2 (pt) planta transgênica; polinucleotídeo recombinante; vetor de expressão expressável em plantas; método para a produção de uma planta transformada tendo fotossíntese aprimorada; e proteína quimérica
EA201590747A1 (ru) Способы лечения с использованием аденовируса
RU2019124676A (ru) СЛИТЫЙ БЕЛОК SIPRα-41BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
BR112019024656A2 (pt) vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
AR095982A1 (es) Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico